Our Medical Affairs team is a peer-based resource for healthcare providers. We are committed to advancing science and medicine through awareness, education, and research.
Find your SMA using the map
Michael Breen, OD
15440 Laguna Canyon Road,
Suite 150
Irvine, CA 92618
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
Find your SMA using the map
The Tarsus research grant program is committed to supporting studies sponsored by qualified third-party investigators or institutions that advance medical and scientific knowledge to healthcare professionals and promotes excellence in patient care. Studies are generally exploratory in nature with smaller sample sizes, or case studies, and offer valuable clinical insights.
Qualified investigators can submit an unsolicited research concept for a research grant aligned with the following strategic areas of interest:
To be considered for review, the proposal must include a short abstract with study objective(s) and outcome measures.
For more information about our research grant program, please reach out to your Senior Medical Ambassador.
As a part of our commitment to advancing science and medicine, Tarsus believes in supporting independent and ethical clinical research, designed and conducted by qualified third-party investigators.
Investigator-initiated trials (IITs) represent investigator-sponsored, scientifically sound studies with capabilities to expand our understanding of our products, improve patient care, and spark new ideas for further disease-related research.
Qualified investigators can submit an unsolicited IIT concept for an investigator-initiated trial aligned with the following strategic areas of interest:
To be considered for review, the proposal must include study objective(s), hypotheses, endpoints, and a short abstract.
For more information about our investigator-initiated trials, please reach out to your Senior Medical Ambassador.
Independent Medical Education Grants
Medical Sponsorships
Tarsus is committed to providing high-quality and consistent medical information. We recognize the importance of having access to trusted, accurate, and balanced clinical and scientific information about our products.
Use this form to contact the Medical Affairs team with any questions you may have.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
August 2024
Abstract
Purpose: To evaluate the ocular and systemic pharmacokinetics of lotilaner ophthalmic solution, 0.25%, following bilateral topical ocular administration of single and repeated doses in rabbits.
HEALTHCARE
July 2024
Abstract
Purpose: Demodex blepharitis, a chronic lid margin disease, is caused by an infestation of Demodex mites, the most common ectoparasites in human skin and eyelids.
Optometry and Vision Science
March 2024
Abstract
Purpose: This study aimed to evaluate the effect of Demodex blepharitis on patients' daily activities and well-being.
Cornea
February 2024
Abstract
Purpose: The aim of this study was to evaluate the long-term outcomes of lotilaner ophthalmic solution, 0.25%, in the treatment of Demodex blepharitis.
Drugs
October 2023
Abstract
Purpose: This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA.
Ophthalmology
October 2023
Abstract
Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution 0.25% compared with vehicle for the treatment of Demodex blepharitis.
Eye & Contact Lens: Science and Clinical Practice
August 2023
Abstract
Purpose: This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors, signs and symptoms, diagnostic techniques, current management options, and emerging treatments.
Cornea
April 2023
Abstract
Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis.
Eye (Lond)
March 2023
Abstract
Purpose: Twelve ocular surface disease experts convened to achieve consensus about Demodex blepharitis (DB) using a modified Delphi panel process.
CLINICAL OPHTHALMOLOGY
February 2023
Abstract
Purpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process.
Clinical Ophthalmology
September 2022
Abstract
Purpose: To evaluate the impact of Demodex blepharitis on patients’ daily activities and quality of life.
Ocular Immunology and Inflammation
August 2022
Abstract
Purpose: To evaluate the efficacy and safety of lotilaner ophthalmic solution, 0.25% eyedrops compared to vehicle for the treatment of Demodex blepharitis.
Contact Lens & Anterior Eye
August 2022
Abstract
Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation compared to vehicle control.
Clinical Ophthalmology
April 2022
Abstract
Purpose: To evaluate the prevalence of Demodex blepharitis by its pathognomonic sign, collarettes, in patients presenting for any reason to eye care clinics in the United States.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
October 2021
Abstract
Purpose: To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with Demodex blepharitis.
Journal of Ophthalmology
September 2021
Abstract
Purpose: To evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis.